-
Capital, M&A & Industry Strategy2 months agoSolstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2
Solstice Oncology has secured $225 million in series A funds to advance a next-gen immunotherapy that the biotech hopes will turn “darkness to light” for cancer...
-
Capital, M&A & Industry Strategy2 months agoNRAS Mutations May Require Mutation-Guided Combination Therapies
Mutant NRAS has remained difficult to target in cancer. New findings suggest that its signaling partnership with wild-type HRAS may offer a targetable vulnerability, but effective...
-
Capital, M&A & Industry Strategy2 months ago
Schrödinger births new immunology and inflammation biotech, Tectora Therapeutics
Schrödinger announced the launch of new immune disease-focused Tectora Therapeutics, which comes online with a $55 million series A financing round.
-
Capital, M&A & Industry Strategy2 months agoNovartis RNA drug falls short in rare muscle disease study
The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s business development acumen, according to one analyst.
-
Capital, M&A & Industry Strategy2 months agoBrainChild Bio targets deadly pediatric brain cancer with $116M series A
BrainChild Bio’s lead asset BCB-276 is in pivotal development for diffuse intrinsic pontine glioma, a rare and fatal brain tumor that affects around 300 children in...
-
Capital, M&A & Industry Strategy2 months agoPharma body sees ‘green shoots’ in UK investment
The UK is starting to benefit from a "real partnership" between pharma and government, reversing years of diminishing investment, says the ABPI.
-
Capital, M&A & Industry Strategy2 months agoNovartis India acquires Pfizer brands for $132m
The purchase adds an established hypertension brand to Novartis’ cardiovascular range. Novartis India’s board cleared the deal, after which the company signed an asset purchase agreement...
-
Capital, M&A & Industry Strategy2 months agoCan Benelux turn scientific strength into larger biotech scale?
Belgium and the Netherlands have built some of Europe's strongest life sciences ecosystems, powered by leading research institutions and a growing pool of experienced biotech talent....
-
Capital, M&A & Industry Strategy2 months ago
BrainChild Bio masterminds $116M series A for CAR-T’s pivotal push in pediatric brain cancer
A startup spawned from Seattle Children’s Hospital has raised a $116 million series A to advance cell therapies for devastating childhood brain tumors.
-
Capital, M&A & Industry Strategy2 months agoGerontology group backs updated immunization guidance
The Gerontological Society of America has thrown its institutional weight behind a sweeping new review of respiratory vaccine evidence, endorsing findings released on September 2, 2026...
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
